For the year ending 2025-12-31, ASBP made $6,202 in revenue. -$24,480,848 in net income. Net profit margin of -394725.06%.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Net revenue | 6,202 | |||
| Cost of revenue | 6,318 | |||
| Gross margin | -116 | |||
| General and administrative (including stock-based compensation of 14.1 million and 0, respectively) | 17,637,432 | |||
| Research and development | 923,914 | |||
| Sales and marketing | 789,829 | |||
| Total operating expenses | 19,351,175 | |||
| Loss from operations | -19,351,291 | |||
| Interest expense | 8,531,275 | |||
| Change in fair value of liabilities | 3,860,889 | |||
| Initial recognition of forward purchase liability | -95,062 | |||
| Loss on extinguishment of debt | -364,109 | |||
| Total other expense, net | -5,129,557 | |||
| Loss before provision for income taxes | -24,480,848 | |||
| Net loss | -24,480,848 | |||
| Diluted EPS | -16.38 | |||
| Basic Average Shares | 1,494,956 | |||
| Diluted Average Shares | 1,494,956 | |||
Aspire Biopharma Holdings, Inc. (ASBP)
Aspire Biopharma Holdings, Inc. (ASBP)